Tag: Quarter

Moelis & Company to Announce First Quarter 2024 Financial Results and Host a Conference Call on April 24, 2024

NEW YORK, April 03, 2024–(BUSINESS WIRE)–Moelis & Company (NYSE: MC), a leading global independent investment bank, will release its first quarter 2024 financial results after the market closes on Wednesday, April 24, 2024.

Ken Moelis, Chairman and Chief Executive Officer, and Joe Simon, Chief Financial Officer, will also host a related conference call at 5:00pm ET on the same day (April 24, 2024) to review the financial results. Following the review, there will be a question and answer session.

Investors and analysts may participate in the live conference call by dialing +1 (888) 300 4150 (domestic) or +1 (646) 970 1530 (international) and using access code 8014191. Please dial in 15 minutes before the conference call begins. The conference call will also be accessible as a listen-only audio webcast through the Investor Relations section of the Moelis & Company website at www.moelis.com.

For those unable to listen to the live broadcast, a replay of the call will be available for one month via telephone starting approximately one hour after the live call ends. The replay can be accessed at +1 800 770 2030 (domestic) or +1 609 800 9909 (international); the conference number is 8014191.

About Moelis & Company

Moelis & Company (“Moelis”) is a leading global independent investment bank that provides innovative strategic advice and solutions to a diverse client base, including corporations, governments and financial sponsors. The Firm assists its clients in achieving their strategic goals by offering comprehensive integrated financial advisory services across all major industry sectors. Moelis’s experienced professionals advise clients on their most critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. The Firm serves its clients from 23 locations in North and South America, Europe, the Middle East, Asia and Australia. For

Read More ...

Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results

Quarterly EsoGuard® revenue increased 33 percent sequentially

Expanding EsoGuard clinical validity and clinical utility data poised to drive medical policy coverage, including line of sight to Medicare coverage

Conference call and webcast to be held tomorrow, March 26th at 8:30 AM ET

NEW YORK, March 25, 2024 /PRNewswire/ — Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( “PAVmed”), today provided a business update for the Company and presented financial results for the year ended December 31, 2023.

Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. (PRNewsfoto/Lucid Diagnostics)

Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. (PRNewsfoto/Lucid Diagnostics)

Conference Call and Webcast

The webcast will take place on March 26, 2024, at 8:30 AM, and be accessible in the investor relations section of the Company’s website at luciddx.com.  Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name “Lucid Diagnostics Business Update” to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company’s website at luciddx.com.

Business Update Highlights

“We are very pleased with the excellent progress Lucid has made on multiple fronts in the fourth quarter and recent weeks,” said Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer. “We saw solid revenue growth on stable test volume and our revenue cycle management processes are yielding improving allowances and stable pricing. Our #CYFT program targeting firefighters and other groups is thriving and we have a

Read More ...

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024

Spero Therapeutics, Inc.

Spero Therapeutics, Inc.

CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Wednesday, March 13, 2024 at 4:30 p.m. ET to report its fourth quarter and full year financial results and provide an update on its business and pipeline.

To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13744458, or click on this Link and request a return call. The audio webcast can be accessed on the “Events and Presentations” page under the “Connect” tab of the Company’s website at www.sperotherapeutics.com. The archived webcast will also be available on Spero’s website for 30 days following the call.

About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, novel therapies for rare diseases and multi-drug resistant (MDR) bacterial infections with high unmet need.

  • Spero Therapeutics is developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.

  • Tebipenem HBr is an investigational drug in the United States being developed for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis, caused by certain bacteria, in adult patients who have limited treatment options; tebipenem HBr is not U.S. Food and Drug Administration (FDA)-approved.

  • Spero Therapeutics also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is in development to treat MDR Gram-negative infections in the hospital setting.

For more information, visit https://sperotherapeutics.com.

Investor Relations Contact: 
Ted Jenkins
Vice President, Investor Relations and

Read More ...

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

  • Net cash used in operating and investing activities was $52.6 million in the fourth quarter and $136.7 million for the full year of 2023; quarter-end cash and restricted cash position was $621.0 million

  • The company expects cash guidance for the full year 2024 net cash used in operating and investing activities to be $208 to $225 million and expects to end the year with approximately $405 million in cash (midpoint)

  • Advanced potential best-in-class Alzheimer’s disease portfolio in 2023: initial data supportive of ongoing Phase 1 clinical trial for PRX012, an anti-amyloid beta antibody; received FDA clearance for IND application and Fast Track designation for PRX123, a dual amyloid beta/tau vaccine; reported Phase 1 data for BMS-986446 (formerly PRX005), an anti-tau antibody, data supports moving into a Phase 2 clinical trial by partner Bristol Myers Squibb

  • Strengthened leadership position in the amyloidosis community with ongoing enrollment of the confirmatory Phase 3 AFFIRM-AL clinical trial of birtamimab in patients with Mayo Stage IV AL amyloidosis; published Phase 3 VITAL clinical trial data in Blood, the peer-reviewed journal of ASH

  • Received $55 million milestone payment from Bristol Myers Squibb in July 2023 for exclusive worldwide license to BMS-986446 (formerly PRX005)

DUBLIN, February 15, 2024–(BUSINESS WIRE)–Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the fourth quarter and full year 2023. In addition, the Company provided 2024 financial guidance and business highlights.

“2023 was a year of strong progress for Prothena as we advanced our protein dysregulation portfolio and moved closer to becoming a fully integrated commercial company. The next 12 to 18 months have the potential to transform Prothena with multiple upcoming clinical readouts across our robust portfolio,” said Gene Kinney, Ph.D.,

Read More ...

RE Royalties Announces Third Quarter 2023 Financial Results and Key Business Highlights

All amounts in Canadian dollars unless otherwise stated

VANCOUVER, BC / ACCESSWIRE / November 27, 2023 / RE Royalties Ltd. (TSX.V:RE)(OTCQX:RROYF) (“RE Royalties” or the “Company“), a global leader in renewable energy royalty-based financing, is pleased to announce the financial results for the third quarter ended September 30, 2023 (“Q3 2023“). For further information on these results please see the Company’s Condensed Consolidated Interim Financial Statements and Management’s Discussion and Analysis for Q3 2023, filed on SEDAR+ at www.sedarplus.com.

Key business and financial highlights for Q3 2023 include:

  • The Company entered into a loan agreement and a royalty agreement with Butler Corporation SpA (“CleanLight”), a Chilean technology company and manufacturer of mobile solar-battery systems including solar lighting towers and solar-hybrid battery generators. The Company provided a US$3 million secured loan to finance CleanLight’s expansion into other countries in Latin America. The CleanLight loan has a two-year term, and bears interest of 12% per annum. The Company also acquired a gross revenue royalty of 5% for a period of 10 years, for US$200,000. The royalty rate will reduce to 3% after certain revenue milestones are met.

  • The Company entered into a loan agreement and a royalty agreement with Revolve Renewable Power Corp. (“Revolve”) to support Revolve’s acquisition of a portfolio of two operational run-of-river hydro projects in British Columbia, and one operational wind project in Alberta with a combined gross capacity of 23 MW (the “Operational Projects”).The Operational Projects receive revenue from Power Purchase Agreements (“PPAs”) with BC Hydro and the City of Medicine Hat, for the hydro projects and the wind project, respectively. The Operational Projects have PPAs with remaining terms ranging from 32-35 years for the hydro projects and 11 years for the wind project. The loan will have a term

Read More ...

Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Spero Therapeutics, Inc.

Spero Therapeutics, Inc.

CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, November 13, 2023 at 4:30 p.m. ET to report its third quarter 2023 financial results and provide an update on its business and pipeline.

To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13741831, or click on this link and request a return call. The audio webcast can be accessed on the “Events and Presentations” page under the “Connect” tab of the Company’s website at www.sperotherapeutics.com. The archived webcast will also be available on Spero’s website for 30 days following the call.

About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases.

  • Spero Therapeutics is developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.

  • Tebipenem HBr is an investigational drug in the United States being developed for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis, caused by certain bacteria, in adult patients who have limited treatment options; tebipenem HBr is not U.S. Food and Drug Administration (FDA)-approved.

  • Spero Therapeutics also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is in development to treat MDR Gram-negative infections in the hospital setting.

For more information, visit https://sperotherapeutics.com.

Investor Relations Contact: 
Ted Jenkins
Vice President, Investor Relations and Strategic

Read More ...

Lightbridge Provides Business Update and Announces Third Quarter 2023 Financial Results

Lightbridge Corporation

Lightbridge Corporation

Conference Call on Tuesday, October 31 at 4 p.m. ET

RESTON, Va., Oct. 30, 2023 (GLOBE NEWSWIRE) — Lightbridge Corporation (Nasdaq: LTBR), an advanced nuclear fuel technology company, announced its financial results for the third quarter ended September 30, 2023, and provided an update on the Company’s continued progress.

Seth Grae, President & Chief Executive Officer of Lightbridge Corporation, commented, “We are making excellent progress on our fuel development efforts. Our recently announced engineering study in Romania is an important advancement for examining Lightbridge Fuel’s feasibility in CANDU reactors. Together with our Strategic Partnership Project Agreement with Idaho National Laboratory that we announced in December and the DOE-funded studies at MIT and Texas A&M relating to our fuel for small modular reactors, we continue to advance towards commercial applications in reactors of today and of the future.”

Financial Highlights

The Company maintained a working capital position at September 30, 2023 of $28.6 million and had no debt.

Cash Flows Summary

Cash and cash equivalents were $29.2 million, as compared to $28.9 million at December 31, 2022, an increase of $0.3 million for the nine months ended September 30, 2023, consisting of the following:

  • Cash used in operating activities for the nine month periods ended September 30, 2023 and September 30, 2022 was $4.1 million.

  • Cash provided by financing activities for the nine months ended September 30, 2023, was $4.5 million, a decrease of $6.1 million compared to $10.6 million in the nine months ended September 30, 2022. This decrease was due to a decrease in the net proceeds from the issuance of common stock by our at-the-market (ATM) facility in the first nine months of 2023.

Balance Sheet Summary
Total assets were $30.1 million, and total liabilities were $0.9 million at September 30, 2023. Working capital was $28.6

Read More ...

InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th

InspireMD, Inc.

InspireMD, Inc.

-Conference call and webcast to be held at 8:30 a.m. EST-

TEL AVIV, Israel and MIAMI, Oct. 30, 2023 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report third quarter 2023 financial results on Monday, November 6th, 2023, before the financial markets open.

Management will host a conference call and webcast with the investment community at 8:30 am (EST) that same day to review financial results and provide an update on corporate developments.

Title:

InspireMD Third Quarter 2023 Financial Results and Corporate Update Conference Call and Webcast

 

 

Date:

Monday, November 6th, 2023

 

 

Time:

8:30 a.m. ET

 

 

Conference Call Details:

Toll-Free: 1-877-407-4018
International: 1-201-689-8471
Conference ID: 13741842
To utilize the Call me™ feature, click here.

 

 

The conference call will be webcast live from the Company’s website and will be available via the following links:

 

Webcast:

Webcast link – click here
https://www.inspiremd.com/en/investors/investor-relations/

The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.

Forward-looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are

Read More ...

Costco delivers a strong quarter, and we see two catalysts ahead

Read More ...

Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update

Turnstone Biologics Corp.

Turnstone Biologics Corp.

  • Successfully closed upsized IPO, raising $88 million in gross proceeds to continue advancing pipeline of Selected TIL Therapy programs

  • Cash position expected to fund operations into second quarter of 2025

  • Two Phase 1 clinical trials of lead program, TIDAL-01, in several solid tumor Indications ongoing

SAN DIEGO, Sept. 01, 2023 (GLOBE NEWSWIRE) — Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to tumor-infiltrating lymphocyte (TIL) therapy, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent business highlights.

“I am extremely proud of the recent achievements of the Turnstone team, including the successful completion of our upsized IPO which, despite challenging current market conditions, is indicative of the potential for Turnstone to deliver transformative therapies to the millions of cancer patients underserved by current treatment options,” said Sammy Farah, Ph.D., M.B.A., Turnstone’s President and Chief Executive Officer. “We are thrilled to bring in new investors through our upsized IPO and to have the continued support of our existing stockholders. With the additional funding and the deeply experienced and dynamic team we have assembled at the Company, Turnstone is strongly positioned to execute on our lead clinical candidate, TIDAL-01, and continue advancing our next-generation Selected TIL therapy pipeline.”

Recent Business Highlights

  • Completed Upsized Initial Public Offering: In July 2023, Turnstone priced its initial public offering (IPO) at $12.00 per share. In connection with the offering, the Company issued 7,318,275 common shares, including 651,608 shares sold in August 2023 pursuant to the exercise of the underwriters’ option to purchase additional shares, and received gross proceeds of approximately $88.0 million before deducting underwriting discounts and commissions and other offering expenses. The shares

Read More ...